Trial reportStem cells translational medicine2012
Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab.
Trial report in Stem cells translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Caught in the crossfire: cardiac complications of cancer therapy.The Journal of clinical investigation · 2026Review
- Generation and applications of cardiac spheroids.npj biomedical innovations · 2025Review
- HER2-Targeted Therapy-From Pathophysiology to Clinical Manifestation: A Narrative Review.Journal of cardiovascular development and disease · 2023Review
- Redox Status Response of Physical Exercise Training in Women with Breast Cancer during Trastuzumab Therapy.Healthcare (Basel, Switzerland) · 2022Article
- Receptor tyrosine kinase inhibitors negatively impact on pro-reparative characteristics of human cardiac progenitor cells.Scientific reports · 2022Article
- Review
- Effects of Cardiotoxins on Cardiac Stem and Progenitor Cell Populations.Frontiers in cardiovascular medicine · 2021Review
- The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes.Clinical and translational medicine · 2017Article
- Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells.Cell death & disease · 2017Article
- EMT/MET at the Crossroad of Stemness, Regeneration and Oncogenesis: The Ying-Yang Equilibrium Recapitulated in Cell Spheroids.Cancers · 2017Review
- Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application.International journal of molecular sciences · 2017Article
- Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs.Oxidative medicine and cellular longevity · 2017Review
- Bone Marrow Is a Reservoir for Cardiac Resident Stem Cells.Scientific reports · 2016Article
- Cardiac toxicity of trastuzumab in elderly patients with breast cancer.Journal of geriatric cardiology : JGC · 2016Review
- Epigenomic Reprogramming of Adult Cardiomyocyte-Derived Cardiac Progenitor Cells.Scientific reports · 2015Article
- A corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicity.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- An update on cardio-oncology.Trends in cardiovascular medicine · 2014Review
- Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.Therapeutic advances in drug safety · 2014Review
- A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy.Circulation. Heart failure · 2014Article
- Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture.Journal of cellular and molecular medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Trastuzumab (TZM), a monoclonal antibody against the ERBB2 protein, increases survival in ERBB2-positive breast cancer patients. Its clinical use, however, is limited by cardiotoxicity. We sought to evaluate whether TZM cardiotoxicity involves inhibition of human adult cardiac-derived stem cells, in addition to previously reported direct adverse effects on cardiomyocytes. To test this idea, we exposed human cardiosphere-derived cells (hCDCs), a natural mixture of cardiac stem cells and supporting cells that has been shown to exert potent regenerative effects, to TZM and tested the effects in vitro and in vivo. We found that ERBB2 mRNA and protein are expressed in hCDCs at levels comparable to those in human myocardium. Although clinically relevant concentrations of TZM had no effect on proliferation, apoptosis, or size of the c-kit-positive hCDC subpopulation, in vitro assays demonstrated diminished potential for cardiogenic differentiation and impaired ability to form microvascular networks in TZM-treated cells. The functional benefit of hCDCs injected into the border zone of acutely infarcted mouse hearts was abrogated by TZM: infarcted animals treated with TZM + hCDCs had a lower ejection fraction, thinner infarct scar, and reduced capillary density in the infarct border zone compared with animals that received hCDCs alone (n = 12 per group). Collectively, these results indicate that TZM inhibits the cardiomyogenic and angiogenic capacities of hCDCs in vitro and abrogates the morphological and functional benefits of hCDC transplantation in vivo. Thus, TZM impairs the function of human resident cardiac stem cells, potentially contributing to TZM cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.